ALPS Medical Breakthroughs ETF (0H6M)
LSE 
Summary
0H6M Chart
Biotech ETF SBIO Can Get Its Groove Back
With rising Treasury yields and the Federal Reserve's recent interest rate hike ranking as the likely culprits, the previously hot ALPS Medical Breakthroughs ETF (SBIO) is in the midst of a correction. That pullback, though, may be a buying opportunity.
SBIO: Promising Pipelines, Insufficient Return Potential
SBIO is rated Sell due to a significant overvaluation vs. its probability-weighted fair NAV of $37.86, far below the $62.22 market price. Current fund pricing capitalizes on large portions of future biotech success, exposing investors to downside if clinical or commercial outcomes disappoint. Despite credible late-stage pipelines and solid cash runways, dilution risk remains high, with modeled scenarios projecting negative annualized returns.
SBIO ETF Rallies on Clinical Trial Wins & M&A Demand
The biotechnology sector continues to ride a massive wave of medical innovation, and ETFs like the ALPS Medical Breakthroughs ETF (SBIO) appear to be capturing the upside. SBIO posted a solid 5% gain in August, fueled by positive clinical trial data and an accelerating pace of industry mergers and acquisitions.
ALPS Medical Breakthroughs ETF (0H6M) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ALPS Medical Breakthroughs ETF ever had a stock split?
ALPS Medical Breakthroughs ETF Profile
| LSE Exchange | US Country |
Overview
The company operates a unique investment fund focusing on a niche within the biotechnology sector. Specifically, it employs a passive management or indexing approach to closely track the performance of an underlying index. This index is carefully selected to represent small and mid-cap biotechnology companies deeply involved in the clinical trial phase of their drug development, especially those in Phase II or Phase III stages as defined by the U.S. Food and Drug Administration (FDA) guidelines. By investing at least 80% of its net assets in securities that comprise the underlying index, the fund aims to provide investors with a focused exposure to the biotechnology sector's potential growth, rooted in its innovative and clinical advancements.
Products and Services
- Passive Management Investment Fund
- Exposure to Small and Mid-Cap Biotechnology Companies
- Customized Index Tracking
This service involves the operation of an investment fund that adopts a passive management or indexing investment strategy. The fund is designed to mirror the performance of its underlying index, which is constituted of small and mid-cap biotechnology companies. These companies are significantly involved in developing drugs that are currently undergoing Phase II or Phase III clinical trials as stipulated by the FDA. This strategy is particularly suited for investors looking to gain exposure to the biotechnology sector's dynamics without actively managing their investments.
Through its targeted investment strategy, the fund offers investors a unique opportunity to invest in small and mid-cap biotechnology companies. This segment is known for its significant growth potential and innovative approaches to drug development. The selection criteria ensure that only companies with drugs in the critical Phase II or Phase III of FDA clinical trials are included, aligning investors with those poised for potential breakthroughs and market impact.
The fund's investment approach is characterized by the creation and tracking of a customized index. This index is carefully constructed to represent a portfolio of biotechnology companies engaged in advanced stages of clinical trials, ensuring a focused and strategic exposure to the sector. This method provides a transparent and efficient way for investors to tap into the biotechnological innovations and advancement, reflecting an in-depth understanding of this market segment's opportunities and risks.
Contact Information
